Previous 10 | Next 10 |
— 12 Weeks of Treatment with EOHILIA May Address Significant Unmet Needs of Patients 11 Years of Age and Older — EoE Is a Chronic Disease That Can Significantly Impact Patients, with Esophageal Inflammation and Intermittent Symptoms of Choking and Difficult or ...
− Primary and Key Secondary Endpoints Were Met in Narcolepsy Type 1 Phase 2b Trial − TAK-861 Was Found to be Generally Safe and Well-Tolerated − Results Will be Presented at an Upcoming Scientific Congress Takeda ( TSE:4502/NYSE...
2024-02-02 17:11:18 ET More on CRISPR Therapeutics, Takeda Pharmaceutical, etc. Takeda Pharmaceutical Company Limited (TAK) Q3 2023 Earnings Call Transcript Crispr Therapeutics: Investors Bet Against Casgevy Uptake Biotech And Pharma Diversification Pays Off ...
2024-02-02 11:17:26 ET More on WisdomTree Japan Hedged Equity Fund: DXJ: Capitalizing On Japan's Bull Market, Mitigating FX Risk DXJ: Forward Indicator Is Showing Signs Of Weakness Tsunami warning in Japan after earthquake; Trading closed for New Year's Seeki...
2024-02-01 09:12:12 ET Protagonist Therapeutics ( NASDAQ: PTGX ) shares gained around 6% premarket on Thursday after the biopharma firm entered into a global license and collaboration deal with Takeda ( NYSE: TAK ) for the development and commercialization of its inv...
IDW Media Holdings, Inc. (IDWM) is expected to report for quarter end 2023-10-31 Deluxe Corporation (DLX) is expected to report $0.62 for Q4 2023 SkyWest Inc. (SKYW) is expected to report $0.11 for Q4 2023 1-800-FLOWERS.COM Inc. (FLWS) is expected to report $1.22 for Q2 2024 Brook...
2024-02-01 02:26:23 ET Takeda Pharmaceutical ( NYSE: TAK ) said that Costa Saroukos, CFO, has decided to leave Takeda to return to his home-country of Australia to be closer to family. ... Read the full article on Seeking Alpha For further details ...
Takeda (TOKYO:4502/NYSE:TAK) today announced that Costa Saroukos, chief financial officer, has decided to leave Takeda to return to his home-country of Australia to be closer to family. Mr. Saroukos will step down as CFO, effective April 1, 2024 and will remain with the company as a board directo...
2024-02-01 01:21:16 ET More on Takeda Pharmaceutical EU okays Takeda's Hyqvia co-formulated with Halozyme's Enhanze Takeda wins EU approval for Hyqvia CIDP indication Seeking Alpha’s Quant Rating on Takeda Pharmaceutical Historical earnings data for Ta...
Two New U.S. FDA Approvals in FY2023 Q3: FRUZAQLA for Adults With Previously Treated Metastatic Colorectal Cancer and ADZYNMA for Ultra-Rare Blood Clotting Disorder cTTP Strong Commercial Execution Maximizing Value of Existing Portfolio: ENTYVIO ® Pen Launched...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
− If Approved in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless of Biomarker Status in Over a Decade − Positive Opinion Based on Results from a Phase 3 Clinical Trial Which Demonstrated Significan...
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO-2 Phase III clinical trial — ...
Neurocrine Biosciences Inc (NASDAQ:NBIX) revealed on Tuesday topline data for its Phase 2 SAVITRI study of NBI-1065845 in adult subjects with maj...